Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes
Authors
Keywords
-
Journal
JAMA Network Open
Volume 5, Issue 10, Pages e2235995
Publisher
American Medical Association (AMA)
Online
2022-10-11
DOI
10.1001/jamanetworkopen.2022.35995
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
- (2021) Juan P. Frias et al. DIABETES CARE
- Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: A network meta-analysis
- (2021) Shi Wence et al. HEART RHYTHM
- Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease
- (2021) Zien Zhou et al. STROKE
- Glucose-lowering drug use and new-onset atrial fibrillation in patients with diabetes mellitus
- (2021) Gregoire Fauchier et al. DIABETOLOGIA
- Sodium‐Glucose Co‐Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
- (2021) Arjun K. Pandey et al. Journal of the American Heart Association
- Prevention and Treatment of Atrial Fibrillation via Risk Factor Modification
- (2021) Evan L. O'Keefe et al. AMERICAN JOURNAL OF CARDIOLOGY
- Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease
- (2021) Elisabetta Patorno et al. ANNALS OF INTERNAL MEDICINE
- Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?
- (2020) Salva R. Yurista et al. Cardiovascular Diabetology
- Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial
- (2020) Thomas A. Zelniker et al. CIRCULATION
- Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map
- (2020) Jianhong Zhu et al. Lancet Diabetes & Endocrinology
- Preventing Atrial Fibrillation With Treatments for Diabetes Mellitus
- (2020) Christopher B. Granger et al. CIRCULATION
- Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials
- (2020) Besmir Nreu et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study
- (2020) Hung-Yi Chen et al. Cardiovascular Diabetology
- Decreased Antihyperglycemic Drug Use Driven by High Out-of-Pocket Costs Despite Medicare Coverage Gap Closure
- (2020) Mugdha Gokhale et al. DIABETES CARE
- SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials
- (2020) Wen-jie Li et al. Cardiovascular Diabetology
- Effect of antidiabetic drugs on the risk of atrial fibrillation: mechanistic insights from clinical evidence and translational studies
- (2020) Ting-Wei Lee et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program
- (2020) Jing Luo et al. JAMA Network Open
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis
- (2019) Moa P. Lee et al. JAMA Dermatology
- Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats
- (2019) Ting-I Lee et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
- (2019) Carlos G. Santos-Gallego et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care
- (2019) Elisabetta Patorno et al. CIRCULATION
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial
- (2019) Subodh Verma et al. CIRCULATION
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats
- (2019) Qingmiao Shao et al. Cardiovascular Diabetology
- Implications of the Propensity Score Matching Paradox in Pharmacoepidemiology
- (2018) John E Ripollone et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- The effect of dapagliflozin treatment on epicardial adipose tissue volume
- (2018) Takao Sato et al. Cardiovascular Diabetology
- Unknown
- (2018) DIABETES OBESITY & METABOLISM
- Unknown
- (2018) DIABETES OBESITY & METABOLISM
- Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis
- (2018) Muhammad Shariq Usman et al. European Journal of Preventive Cardiology
- Use of Health Care Databases to Support Supplemental Indications of Approved Medications
- (2018) Michael Fralick et al. JAMA Internal Medicine
- Antihyperglycemic drugs use and new-onset atrial fibrillation: A population-based nested case control study
- (2018) Yi-Sheng Liou et al. PLoS One
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- Canagliflozin and Stroke in Type 2 Diabetes Mellitus
- (2018) Zien Zhou et al. STROKE
- Measuring Frailty in Medicare Data: Development and Validation of a Claims-Based Frailty Index
- (2017) Dae Hyun Kim et al. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of incident atrial fibrillation in gout: a cohort study
- (2015) Seoyoung C Kim et al. ANNALS OF THE RHEUMATIC DISEASES
- Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control
- (2015) A.J. Scheen et al. DIABETES & METABOLISM
- Effects of GLP-1 Receptor Agonists on Heart Rate and the Autonomic Nervous System Using Holter Electrocardiography and Power Spectrum Analysis of Heart Rate Variability
- (2015) Yuki Nakatani et al. DIABETES CARE
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY – CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN – 2015
- (2015) Yehuda Handelsman et al. Endocrine Practice
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exendin-4 Prevents Vascular Smooth Muscle Cell Proliferation and Migration by Angiotensin II via the Inhibition of ERK1/2 and JNK Signaling Pathways
- (2015) Kosuke Nagayama et al. PLoS One
- Impact of Intensive Glycemic Control on the Incidence of Atrial Fibrillation and Associated Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study)
- (2014) Omid Fatemi et al. AMERICAN JOURNAL OF CARDIOLOGY
- Introduction
- (2014) DIABETES CARE
- Atrial fibrillation among Medicare beneficiaries hospitalized with sepsis: Incidence and risk factors
- (2013) Allan J. Walkey et al. AMERICAN HEART JOURNAL
- Metrics for covariate balance in cohort studies of causal effects
- (2013) Jessica M. Franklin et al. STATISTICS IN MEDICINE
- Standards of Medical Care in Diabetes--2013
- (2012) DIABETES CARE
- Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study
- (2011) Rachel R Huxley et al. HEART
- A combined comorbidity score predicted mortality in elderly patients better than existing scores
- (2011) Joshua J. Gagne et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- A Simple Approach to the Estimation of Incidence Rate Difference
- (2010) Y. Xu et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study
- (2009) Renate B Schnabel et al. LANCET
- Impact of New-Onset Diabetes Mellitus on Development of Atrial Fibrillation and Heart Failure in High-Risk Hypertension (from the VALUE Trial)
- (2008) Tonje Amb Aksnes et al. AMERICAN JOURNAL OF CARDIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search